Literature DB >> 2659539

High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas.

K Grünewald1, J Lyons, A Fröhlich, H Feichtinger, R A Weger, G Schwab, J W Janssen, C R Bartram.   

Abstract

The frequency of Ki-ras gene mutations was studied in 100 paraffin-embedded sections obtained from 63 pancreatic adenocarcinomas by in vitro amplification of target sequences via polymerase chain reaction (PCR) and selective oligonucleotide hybridization. Forty-seven (75%) of the tumors contained a Ki-ras mutation at codon 12. No predominant amino acid substitution or nucleotide transition at this codon was observed. Two carcinomas exhibited 2 distinct Ki-ras mutations. No particular correlation could be established between the incidence of Ki-ras mutation and clinical parameters (sex, age, survival), tumor grade or tumor stage.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2659539     DOI: 10.1002/ijc.2910430614

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  75 in total

Review 1.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  A case of synchronous pancreatic ductal adenocarcinoma and ovarian mucinous cystic neoplasm: use of kras mutation molecular phenotyping to demonstrate independent primary origin.

Authors:  Maeve Lowery; David Klimstra; Cyrus Hedvat; William Jarnagin; Dennis Chi; Eileen M O'Reilly
Journal:  Gastrointest Cancer Res       Date:  2012-03

3.  Molecular genetic analysis of DNA obtained from fixed, air dried or paraffin embedded sources.

Authors:  K Grünewald; J Lyons; T E Hansen-Hagge; J W Janssen; H Feichtinger; C R Bartram
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

4.  K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers.

Authors:  K Sugio; K Molberg; J Albores-Saavedra; A K Virmani; Y Kishimoto; A F Gazdar
Journal:  Int J Pancreatol       Date:  1997-06

5.  Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines.

Authors:  R A Perugini; T P McDade; F J Vittimberga; A J Duffy; M P Callery
Journal:  J Gastrointest Surg       Date:  2000 Jan-Feb       Impact factor: 3.452

6.  Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM).

Authors:  Asfar Sohail Azmi; Aamir Ahmad; Sanjeev Banerjee; Vivek M Rangnekar; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Pharm Res       Date:  2008-04-22       Impact factor: 4.200

7.  Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results.

Authors:  Thomas Semrad; Afsaneh Barzi; Heinz-Josef Lenz; Irene M Hutchins; Edward J Kim; I-Yeh Gong; Michael Tanaka; Laurel Beckett; William Holland; Rebekah A Burich; Leslie Snyder-Solis; Philip Mack; Primo N Lara
Journal:  Int J Clin Oncol       Date:  2014-08-05       Impact factor: 3.402

8.  Expression of p53 protein in pancreatic adenocarcinoma. Relationship to cigaret smoking.

Authors:  E U Lee; M L Cibull; E O'Daniel-Pierce; W E Strodel; C D Jennings
Journal:  Int J Pancreatol       Date:  1995-06

9.  Pancreatic adenocarcinomas frequently show p53 gene mutations.

Authors:  A Scarpa; P Capelli; K Mukai; G Zamboni; T Oda; C Iacono; S Hirohashi
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

10.  Evidence for aldosterone-dependent growth of renal cell carcinoma.

Authors:  Sharon King; Susan Bray; Sarah Galbraith; Lesley Christie; Stewart Fleming
Journal:  Int J Exp Pathol       Date:  2014-05-07       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.